183 related articles for article (PubMed ID: 23708559)
1. Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims Database.
Baser O; Burkan A; Baser E; Koselerli R; Ertugay E; Altinbas A
Rheumatol Int; 2013 Oct; 33(10):2577-84. PubMed ID: 23708559
[TBL] [Abstract][Full Text] [Related]
2. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
[TBL] [Abstract][Full Text] [Related]
3. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
4. Annual costs of rheumatoid arthritis in Turkey.
Malhan S; Akbulut LA; Bodur H; Tulunay CF
Rheumatol Int; 2010 Mar; 30(5):637-41. PubMed ID: 19582459
[TBL] [Abstract][Full Text] [Related]
5. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
Shi Q; Li KJ; Treuer T; Wang BCM; Gaich CL; Lee CH; Wu WS; Furnback W; Tang CH
PLoS One; 2018; 13(4):e0193489. PubMed ID: 29624580
[TBL] [Abstract][Full Text] [Related]
6. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
[TBL] [Abstract][Full Text] [Related]
7. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
8. Health care costs associated with ankylosing spondylitis in Turkey: an analysis from nationwide real-world data.
Baser O; Burkan A; Baser E; Koselerli R; Ertugay E; Altinbas A
Int J Rheumatol; 2013; 2013():139608. PubMed ID: 23509465
[TBL] [Abstract][Full Text] [Related]
9. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
Grabner M; Boytsov NN; Huang Q; Zhang X; Yan T; Curtis JR
Arthritis Res Ther; 2017 May; 19(1):92. PubMed ID: 28506320
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
13. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
[TBL] [Abstract][Full Text] [Related]
14. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
[TBL] [Abstract][Full Text] [Related]
15. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
16. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
Kamata Y; Minota S
Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
[TBL] [Abstract][Full Text] [Related]
17. One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry.
Fellous S; Rkain H; Ahid S; Abouqal R; Tahiri L; Hmamouchi I; Achemlal L; El Bouchti I; El Maghraoui A; Ghozlani I; Hassikou H; Harzy T; Ichchou L; Mkinsi O; Niamane R; Bahiri R; Allali F
Rheumatol Int; 2021 Apr; 41(4):787-793. PubMed ID: 33386900
[TBL] [Abstract][Full Text] [Related]
18. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?
Eriksson JK; Johansson K; Askling J; Neovius M
Ann Rheum Dis; 2015 Apr; 74(4):648-54. PubMed ID: 24323395
[TBL] [Abstract][Full Text] [Related]
19. Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey.
Ayan G; Esatoglu SN; Hatemi G; Hamuryudan V
Rheumatol Int; 2020 Jul; 40(7):1037-1044. PubMed ID: 32253500
[TBL] [Abstract][Full Text] [Related]
20. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database.
Cho SK; Sung YK; Choi CB; Kwon JM; Lee EK; Bae SC
Rheumatol Int; 2013 Dec; 33(12):2985-92. PubMed ID: 23918169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
